Lundbeck Secures Orphan Drug Designation in Japan for Novel ACTH-Targeting Antibody Asedebart
核心洞察
Lundbeck received orphan drug designation in Japan for asedebart (搜索), a first-in-class anti-ACTH monoclonal antibody targeting congenital adrenal hyperplasia (搜索) and Cushing's disease (搜索).
The investigational therapy addresses a shared underlying mechanism of elevated ACTH levels in both rare endocrine disorders, which affect thousands of patients globally.
Asedebart (搜索) has previously received orphan drug designations in the EU and US, with proof-of-concept clinical trials currently evaluating its efficacy and safety profile.
Lundbeck announced that Japan's Ministry of Health, Labour and Welfare has granted orphan drug designation for asedebart (搜索) (Lu AG13909), a novel anti-ACTH monoclonal antibody being developed for congenital adrenal hyperplasia (搜索) (CAH) and Cushing's disease (搜索). The designation represents a significant regulatory milestone for the investigational therapy targeting rare endocrine disorders characterized by excess adrenocorticotropic hormone production.
Targeting a Shared Disease Mechanism
Both CAH and Cushing's disease (搜索) share an underlying mechanism involving elevated ACTH levels, despite having distinct origins and clinical presentations. In CAH, impaired cortisol production leads to chronically elevated ACTH levels, resulting in excess adrenal androgen production and requiring lifelong hormone replacement therapy. Cushing's disease, by contrast, is caused by overproduction of ACTH by a pituitary adenoma, leading to chronic cortisol excess.
CAH affects approximately 1 in 14,000–18,000 live births worldwide, while Cushing's disease (搜索) has a global prevalence of approximately 2.2 cases per 100,000 people. Both conditions are associated with substantial disease burden, including metabolic, cardiovascular, and neuropsychiatric complications, and are linked to increased morbidity and mortality.
Novel Mechanism of Action
Asedebart (搜索) is a humanized anti-ACTH monoclonal antibody that specifically recognizes ACTH with high affinity. The therapy blocks the binding of ACTH to the melanocortin 2 receptor (搜索) in the adrenal glands, thereby inhibiting neurohormonal signaling of ACTH. This inhibition causes decreased secretion of glucocorticoids, mineralocorticoids and androgens from the adrenal glands.
"CAH and Cushing's disease (搜索) are serious, chronic conditions that can have a profound impact on patients' lives," said Johan Luthman, EVP and Head of Research and Development at Lundbeck. "The investigational program for asedebart (搜索) demonstrates Lundbeck's commitment to deepen our efforts in rare diseases and endocrinological conditions with links to brain function."
Clinical Development Progress
Lundbeck is currently conducting proof-of-concept clinical trials evaluating the efficacy and safety of asedebart (搜索) in patients with classic CAH and Cushing's disease (搜索). The therapy is advancing as a potential first-in-class treatment for conditions characterized by excess ACTH, targeting an underlying disease mechanism rather than managing symptoms.
Asedebart (搜索), formerly designated Lu AG13909, has recently been assigned an International Nonproprietary Name and has received Orphan Drug Designation for CAH in both the European Union and the United States prior to the Japanese designation.
Addressing Treatment Limitations
Current treatment approaches for both conditions aim to manage hormonal imbalance but are associated with important limitations such as variable efficacy and tolerability. In classic CAH, balancing physiological glucocorticoid replacement and control of hyperandrogenism remains a challenge, with risks of long-term consequences from glucocorticoid overtreatment.
For Cushing's disease (搜索), first-line treatment involves surgical removal of the pituitary tumor; however, not all patients are eligible or achieve sustained remission. Current medical treatment options have variable efficacy and may be associated with safety and tolerability limitations.
People with 21-hydroxylase deficiency, the most common form of classic CAH, are at risk of adrenal crisis, a life-threatening condition contributing to increased mortality throughout life. The condition is characterized by enzyme deficiency affecting adrenal steroidogenesis, leading to cortisol and aldosterone deficiency.
Market Significance
The Japanese orphan drug designation provides Lundbeck with regulatory incentives to advance development in one of its focus markets. Japan represents a significant opportunity for addressing unmet medical needs in patients living with CAH and Cushing's disease (搜索), conditions where current therapeutic options remain limited.
Asedebart (搜索) remains an investigational compound not approved for marketing by any regulatory authority worldwide, and its efficacy and safety have not been established. The ongoing proof-of-concept trials will be critical in determining the therapy's potential to address the significant unmet needs in these rare endocrine disorders.